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Abstract
Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right
ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The
disease course is monitored by pulmonary artery systolic pressure measurement via transthoracic echocardiography. A
simple non-invasive test to frequently monitor the patients is much needed. Search for a novel biomarker that can be
detected by a simple test is ongoing and many different options are being studied. Here we review some of the new
and unique pre-clinical options for potential pulmonary hypertension biomarkers. These biomarkers can be broadly
categorized based on their association with endothelial cell dysfunction, inflammation, epigenetics, cardiac function,
oxidative stress, metabolism,extracellular matrix, and volatile compounds in exhaled breath condensate. A biomarker that
can be detected in blood, urine or breath condensate and correlates with disease severity, progression and response to
therapy may result in significant cost reduction and improved patient outcomes.
Background
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare yet
deadly disease with many causes ranging from idiopathic
to secondary to many underlying pathologies including
congenital heart diseases. The disease course is monitored
by pulmonary artery systolic pressure measurement via
transthoracic echocardiography. The confirmatory and
gold standard is the right heart catheterization. This inva-
sive test is used for diagnosis as well as for prognosis of
the disease. For obvious reasons, a non-invasive test to
monitor patients frequently will be invaluable. Therefore,
the search for a biomarker that can be detected by a
simple blood test is ongoing, and many different op-
tions are being studied. This literature review outlines
some of the selected novel candidates for a potential
biomarker for diagnosis and prognosis of PAH. These
biomarkers are broadly categorized based on their rela-
tionship to endothelial cell dysfunction, inflammation,
epigenetics, cardiac function, oxidative stress, metabol-
ism, extracellular matrix, and volatile compounds
(Table 1).
Overview of a selection of novel biomarkers for
pulmonary hypertension
Endothelial cell markers
Asymmetric dimethylarginine (ADMA) ADMA is a
natural amino acid and endogenous inhibitor of nitric
oxide (NO) production. Its role has been studied in
cardiovascular diseases for many years. ADMA is gener-
ated from methylation of arginine residues by protein
arginine methyltransferases and subsequent proteolysis,
while its elimination is achieved mainly by degradation
with dimethyl arginine dimethyl aminohydrolase. The
research by Zhang et al. showed that endothelial injury
can cause increase in plasma ADMA concentration. The
ADMA concentrations are associated with reduced produc-
tion of NO, affecting NO/cGMP pathway and thus leading
to increase in vascular tone. The authors contended that
the antioxidative potential is decreased and ADMA
concentrations can be a useful biomarker for PAH pro-
gression [54].
In an earlier study, Giannakoulas et al., showed that
ADMA may induce pulmonary endothelial dysfunction
via changes in the expression and activity of connexin 43
[9]. Connexins are transmembrane proteins that form
hemichannels and gap junctions on the cell membranes,
and are involved with the transfer of small signaling
molecules between the cytoplasm and extracellular space
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Table 1 A comprehensive table showing the different groups of biomarkers discussed in this review along with the number of subjects, major findings and limitations of the
individual studies
Biomarkers Subjects Major finding/limitations
Endothelial cell Markers ADMA PAH (35) Increased serum concentration in PAH correlated significantly with mPAP and PVR [54].
CTR (35)
PAH-CHD (30) No correlation between the significantly increased ADMA concentration in PAHCHD
patients and hemodynamic parameters [39].
CHD (20)
CTR (20)
Circulating angiogenic
modulatory factors
PAH (97) Serum concentrations of sEng, sVEGFR1 and CRP were all elevated in PAH patients
with sEng having the greatest predictive value for PAH. sEng and CRP were
determined to be the most sensitive independent markers for predicting survival [25].CTR (56)
PCEB-ACE iPAH (25) These new techniques allow for the assessment of endothelial function in vivo,
but these are currently only for research purposes [32].
PAH-CTD (19)
CTR (23)
Inflammatory markers GDF-15 PAH-naïve (76) Significant upregulation in PAH correlated with mean RAP. Plasma
concentrations > 1200 ng.L-1 increased the risk of death [30].
PAH-treated (22)
Galectin-3 PAH (15) Significantly increased in serum of PAH patients which correlated with RV hemodynamics [8].
CTR (10)
OPN iPAH (70) Increased plasma concentration in PAH correlated with NYHA functional class. 4 year survival
rate increased in concentrations < 34.5 ng.mL-1 [23].
CTR (40)
MIF Ssc-PAH (15) Circulating concentration is significantly increased in Ssc-PAH vs. Ssc and correlated with
NYHA functional class [44].
Ssc (14)
NLR PAH (n = 101) Significant correlation with NYHA functional class and mortality; but not an independent
predictor of mortality [34].
Serum BCL-2 Child-PH (35) Increased sBCL-2 concentration correlated with NYHA functional class [1].
CTR (38)
miR iPAH (12) Lists circulating miR that are differentially expressed in PAH vs. control [40].
CTR (10)
Heart function BNP/NTproBNP and RDW iPAH (139) Plasma NT-proBNP is significantly correlated with PVR, CI, and mean RAP. RDW predicted
survival independently from NTproBNP and the 6MWD test [37].
CTR (40)
Cystatin C PAH (14) Significantly correlates with cardiac and hemodynamic parameters [7].
CTR (10)
Homocysteine PAH-CHD (30) Significant increasein PAH-CHD compared to other groups but no hemodynamic correlation
was found [39].
CHD (20)
CTR (20)
Cardiac troponin PAH (167) Increased concentration of cardiac troponin correlates with mortality [48].
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Table 1 A comprehensive table showing the different groups of biomarkers discussed in this review along with the number of subjects, major findings and limitations of the
individual studies (Continued)
New cardiovascular biomarkers MRproADM HF (728) Significant correlation between increased plasma concentration of MRproADM and
mortality [15].
CT-proET1 PAH (28) Blood concentration increased with WHO functional class and correlated with mortality [43].
Copeptin PAH (92) Expression correlated with survival and disease severity [43].
dCTR (39)
hCTR (14)
Oxidative stress F2-Isoprostanes PAH (110) Patients with urine concentration above the median have an increased risk of death [4].
Oxidized lipids PAH (28) Significantly increased in serum of PAH patients vs. control [38].
CTR (21)
GSH PAH (12) Significantly decreased in plasma of PAH patients [54].
CTR (12)
Metabolic biomarkers Fisher ratio PH (140) Decreases with PH severity. Most measured amino acid levels were significantly higher in
patients with PAH [52].
CTR (140)
Tryptophan metabolites PAH (35) Anthranilate and Quinolinate were increased with PVR above 2 [21].
CTR (36)
Gherlin PAH (20) Plasma levels were significantly increased in PAH and correlated with PASP [53].
CTR (20)
ECM MMP-2 TIMP-4 PAH (36) All three proteins were significantly increased in plasma of PAH patients but did not
distinguish between functional classes [41].
TNC CTR (44)
Volatile compounds PAH (27) May allow the detection of PAH specific volatile compounds [26].
CTR (30)
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and between connecting cells. Among connexins, suppress-
ing connexin 43 expression or function promotes skin
wound closure and granulation tissue formation, and may
alleviate scarring, but the mechanisms are not well under-
stood. How ADMA affects connexins is yet to be studied.
In a study by Sanli et al., the authors studied the concen-
trations of ADMA in pediatric patients with congenital
heart disease. The concentrations were elevated in patients
with PAH and congenital heart disease and they made the
recommendations for large prospective clinical studies
before establishing it as a biomarker [39].
Circulating angiogenic modulatory factors Circulating
angiogenic modulatory factors, which are believed to
regulate angiogenesis, are also being studied for their
role as biomarkers for patients with PAH. Malhotra et
al. investigated the concentrations of soluble endoglin,
soluble vascular endothelial growth factor receptor-1
(sVEGFR1), N-terminal brain natriuretic peptide
(NTproBNP), C-reactive protein (CRP), and other bio-
markers in peripheral blood in 97 patients with PAH.
They found that circulating angiogenic proteins like
soluble endoglin and sVEGFR1 concentrations were in-
creased. They also obtained lung tissue from patients
and studied the endoglin expression in microvascular
endothelium and found that the expression was signifi-
cantly enhanced [25]. Tiede et al. confirmed these results
in a study with 76 PAH patients at the time of diagnosis,
but they didn’t find a correlation between sVEGFR1 or
placental growth factor and haemodynamic parameters,
6-min walk distance or survival [46]. Al-Naamani et al.
recently showed that lower von Willebrand factor activity
at baseline was associated with an increased risk of death
or lung transplantation in patients with PAH [2].
Damico et al. investigated the relationship of a potent
angiostatic factor, endostatin, with disease severity and
mortality in PAH. Serum endostatin correlated with poor
functional status, decreased exercise tolerance, and inva-
sive hemodynamic variables. Furthermore, serum endosta-
tin was a strong predictor of mortality [5]. Another study
demonstrated the usefulness of circulating angiopoietins
as biomarkers. In this study Kumpers et al. demonstrated
that angiopoietin 2 blood concentration correlates with
pulmonary vascular resistance making it an accurate
survival predictor [16].
Pulmonary capillary endothelium-bound angiotensin
converting enzyme (PCEB-ACE) PCEB-ACE activity
has been recently highlighted as a marker of pulmonary
endothelial function in several diseases including idiopathic
PAH, PAH associated with connective tissue disease and in
systemic scleroderma without any sign of PAH [17, 32].
Moreover, Langleben et al. recently demonstrated that
during a challenge with epoprostenol, patients who didn’t
respond to the treatment had a decreased activity of PCEB-
ACE. Conversely, PCEB-ACE activity did not decrease in
responding patients [18].
Inflammatory markers
Growth Differentiation Factor-15 (GDF-15) GDF-15
is a murine transforming growth factor β superfamily
member and highly expressed in the adult liver. It is a
stress responsive cytokine and plays a role in regulating
inflammatory pathways during a disease and tissue in-
jury. Nicket et al., showed that GDF-15 concentrations
are elevated in patients with tissue hypoxia, acute coronary
syndrome, pulmonary embolism and in patients with idio-
pathic PAH (iPAH). This increase in GDF-15 concentra-
tions may be explained by the involvement of multiple
stress pathways in cardiac tissue injury and, therefore, can
be utilized as an indicator of disease prognosis [30].
The authors found that GDF-15 enhances the prognostic
information provided by more established biomarkers, in-
cluding NTproBNP, as measured by clinical indicators like
six-minute walk distance. However, GDF-15 is not a cardiac
specific cytokine, so its use as an independent biomarker is
questionable. More studies are needed before it can be
established as a prognostic marker.
Galectin-3 Galectin-3 is secreted by macrophages in
response to mechanical and neurohormonal stimuli. It
works as an endocrine and paracrine factor to stimulate
other macrophages, fibroblasts, and inflammatory cells.
There is evidence for its significance in patients with
heart failure [12]. This is based on its increased concen-
trations in patients with left heart failure where it is be-
lieved to play a major role in cardiac remodeling and
fibrosis. Recently Fenster et al. studied the concentra-
tions of galectin-3 in patients with RV dysfunction and
PAH. They performed echocardiography and measured
blood concentrations of galectin-3 on the same day in
15 patients with PAH and found a significant correlation
between RV morphological changes and galectin-3 con-
centrations. Galectin-3 concentrations are elevated in all
patients with PAH [8]. Galectin-3 has a limited role in
PAH when used as a sole biomarker. Its concentrations
are elevated in patients diagnosed with other diseases in-
cluding renal failure and pulmonary and hepatic fibrosis
[22]. Nonetheless, its use could be of interest in combin-
ation with others biomarkers.
Osteopontin (OPN) OPN is another cytokine that is in-
creased when inflammatory or neoplastic processes activate
the signaling pathways. OPN also activates inflammatory
cells including macrophages, macrocytes, and lymphocytes.
Our lab observed increased circulating plasma OPN
concentrations in rats with Monocrotaline-induced PAH
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that responded to therapy [28]. This finding was vali-
dated in patients by Lorenzen et al. Their study con-
cluded that patients with iPAH had increased OPN
concentrations. Circulating OPN concentrations were
especially helpful in monitoring patient response to thera-
peutic intervention [23]. Lorenzen et al. showed that OPN
correlated with exercise capacity and functional class and
was an independent predictor of survival. Since elevated
OPN concentrations are not specific to iPAH, more studies
are needed to establish its benefits as prognostic biomarker
in patients with iPAH.
Macrophage migration inhibitory factor (MIF) In a
recent study, Le Hiress et al. found that concentrations
of circulating MIF were increased in the serum of patients
with PAH compared to control subjects, and it implicated
T-cell lymphocytes as the source of this overabundance.
Furthermore, they found that curative treatments with the
MIF antagonist ISO-1 or anti-CD74 neutralizing antibodies
partially reversed the development of PH in rats and sub-
stantially reduced inflammatory cell infiltration [19].
Stefanantoni et al., recently found significantly higher
circulating concentrations of MIF and stem cell growth
factor β (SCGF β) in patients with iPAH and with PAH
secondary to systemic sclerosis. Higher concentrations
of MIF were found in patients with an higher NYHA
class– indicating that MIF could be used as a prognostic
marker [44].
Neutrophil-to-lymphocyte ratio (NLR) In a clinical
study, Özpelit et al., recently discovered that NLR was cor-
related with well-established prognostic markers in PAH
such as NYHA functional class, BNP concentrations, and
tricuspid annular plane systolic excursion [34].
Serum BCL-2 (sBcl-2) Akin et al., assessed concentra-
tions of sBcl-2 in children with PH and reported that there
was an increase in the concentrations of sBcl-2 as an in-
flammatory marker and that the sBcl-2 concentrations are
associated with prognostic parameters in children with
PH [1].
Chemokine CXC ligand 13 (CXCL13) Chemokine CXC
ligand 13 (CXCL13) has been implicated in perivascular
inflammation and pulmonary vascular remodeling in
patients with IPAH. Olsson et al. investigated whether
CXCL13 may also play a role in chronic thrombo-
embolic pulmonary hypertension (CTEPH) and whether
serum levels of CXCL13 might serve as biomarkers in
IPAH and CTEPH. CXCL13 was overexpressed in pulmon-
ary vascular lesions of patients with IPAH and CTEPH, and
increased serum concentrations were found in patients with
IPAH and CTEPH, suggesting a potential pathogenic role
of CXCL13 in both diseases. The authors concluded that
given the weak associations between serum CXCL13 and
markers of disease severity and outcome, CXCL13 is un-
likely to become a promising biomarker in these patient
populations [31].
MicroRNAs as biomarkers in PAH
MicroRNAs (miRNAs) are small non-protein coding genes,
which function in RNA silencing and post-transcriptional
regulation of gene expression. miRNAs circulate in the
blood, and their concentrations can be a reflection of exist-
ing vascular pathology.
Sarrion et al., demonstrated the role of miR23a, miR-130,
miR-191, miR-204, miR-145, miR-27a, miR-328, miR-1-2,
miR-199, and miR-744 as potential biomarkers of iPAH.
Out of these, miR-23a is of special interest because of its re-
lation to pulmonary function. It is also believed to regulate
the transcription of genes implicated in PH disease progres-
sion including peroxisome proliferation-activated receptor
(PPAR) γ coactivator-1α (PGC1α), which is currently being
studied as a potential biomarker for PH progression
[40]. In a rat model of PH, Paulin et al. found that serum
tumor necrosis factor-α concentrations progressively in-
creased with time while serum miR-208 concentrations
decreased which mirrored its concentrations in the dis-
eased RV myocardium [35].
Heart function related biomarkers
B-type natriuretic peptide (BNP) and amino-terminal
pro-B-type natriuretic peptide (NTproBNP) BNP and
NTproBNP are the only biomarkers recommended by
the current guidelines for risk stratification in PAH.
However only BNP is cited in guidelines addressing
PAH treatment endpoints: a “normal” BNP is suggested
as a treatment goal. This is true for both adults and
pediatric patients. The relevance of BNP and NTproBNP as
markers of disease progression are known since almost
20 years for IPAH and associated PAH [29, 51]. A retro-
spective study done by Takatsuki et al., studied 88 children
with PH found that BNP and NTproBNP are strong
predictors of disease progression and mortality. However
BNP correlates better with the hemodynamic changes
because of its shorter half-life and NTproBNP is a better
mortality predictor [45]. NTproBNP concentration is not
only a good predictor of survival in PAH, but also a good
marker of treatment efficacy. Indeed, Andreassen et al.
demonstrated a decrease of NTproBNP concentration in
PAH patients responding to therapy [3]. Furthermore, a
retrospective study demonstrated that a NTproBNP con-
centration ≥1256 pg.mL-1 at the time of diagnosis was a
predictor of poor outcome. Also the same study
highlighted the fact that a decrease of 15 % of
NTproBNP concentration was associated with survival
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in their patient’s cohort [27]. Al-Naamani et al. recently
showed that lower vWF activity and cholesterol con-
centrations and higher NTproBNP concentrations at
baseline were associated with an increased risk of death
or lung transplantation in patients with PAH [2].
Red Cell Distribution Width (RDW) RDW has been
studied as a biomarker for outcomes in patients with car-
diovascular diseases [6, 47]. Its relation with carotid athero-
sclerosis in hypertension has been explained [50]. RDW is
being studied as another potential biomarker for measure-
ment of prognosis in patients with iPAH. In a study by
Rhodes et al., the authors studied 139 patients with iPAH.
Their approach was to study multiple biomarkers and focus
on RDW, GDF-15, IL-6, creatinine and NTproBNP. They
measured these biomarkers in the patients and found that
their concentrations were related to the disease severity.
Additionally, the authors found that if RDW is measured
along with NTproBNP, it can significantly help in disease
severity measurement and can potentially be a significant
prognosis indicator [37].
Cystatin C Cystatin C has been studied as a potential
biomarker in patients with PAH. It is used as an indica-
tor for renal filtration and is measured in patients with
renal insufficiency. Fenster et al. studied the correlation
of serum cystatin C concentrations and anatomical and
physiological parameters of right ventricular function.
They found abnormally high concentrations in patients
with PAH which correlated with right ventricular func-
tion [7]. While the study sample was small, and included
ten patients and controls, the cystatin C concentrations
were significantly elevated in patients with PAH. Cystatin
C can be used along with the BNP and NTproBNP and is
independent of age, gender or muscle mass making it a
potentially more desirable biomarker in PAH.
Elevated homocysteine In a study by Sanli et al., the
authors studied the relationship of homocysteine and
ADMA concentrations in patients with congenital heart
disease. They found increased concentrations in patients
having PAH and congenital heart disease but no correl-
ation was found between hemodynamic parameters and
homocysteine concentration. They also found that this
increase in concentration was more significant in cyan-
otic patients as compared to the ones without cyanosis
[39]. In another study done in patients with CHD, Ozerol
et al. also revealed increased homocysteine concentrations
in patients with CHD and PAH as compared to patients
who had left to right shunt surgery and no PAH [33].
However still a large-scale clinical study is required to rec-
ommend homocysteine as a biomarker for diagnosis and
prognosis of PAH.
Cardiac troponin I Velez-Martinez et al. reported cardiac
troponin I concentrations, detectable with a novel highly
sensitive assay, in PAH patients with more severe
hemodynamic and cardiac structural abnormalities
[48]. Cardiac troponin I levels, detectable with this
novel highly sensitive assay, identify patients with PAH who
have more severe hemodynamic and cardiac structural ab-
normalities and provide novel and independent prognostic
information. This highly sensitive assay has the potential to
detect more at-risk patients and improve current risk-
stratification algorithms.
New cardiovascular biomarkers During recent years,
the new cardiovascular biomarkers mid-regional pro-
adrenomedullin (MR-proADM), mid-regional proatrial
natriuretic peptide (MR-proANP), Copeptin, and carboxy-
terminal pro-endothelin-1 (CT-proET1) have been sug-
gested to predict prognosis and aid clinical decision-making
in various cardiopulmonary diseases [13, 15, 24, 43]. Kolditz
et al., recently studied the correlation between biomarkers
and hemodynamic and exercise parameters in PAH patients.
They concluded that different biomarkers reflect dis-
tinctive disease aspects in PAH. NTproBNP best pre-
dicts hemodynamic impairment while MR-proADM
strongly correlates with exercise capacity [14]. In an
interesting study, Volkers et al., demonstrated the increase
of myocardial high-sensitive Troponin T in patients with
PAH in response to maximal physical exercise while con-
centrations of other biomarkers remained constant after
exercise testing [49]. Heresi et al. demonstrated that low
plasma high-density lipoprotein cholesterol (HDL-C) is as-
sociated with higher mortality and clinical worsening in
PAH [10]. Zhao et al. demonstrated that serum HDL chol-
esterol levels might serve as an indicator of disease severity
and prognosis in patients with IPAH [55].
Oxidative stress related biomarkers
Inflammation and oxidative stress are essential in PAH
with increased lipid peroxidation and reduced antioxi-
dant defenses [36].
F2-Isoprostanes The hunt for biomarkers for iPAH is
not limited to blood and serum. A few studies have
looked for biomarkers in other biofluids. One of these
studies was done by Cracowski et al. prospectively. They
studied a compound called F2-isoprostanes in urine
samples of 110 adults. This compound is considered as a
marker of oxidative stress and its exact source has not
been confirmed yet. They found that F2-isoprostane is
an independent predictor of three-year mortality in pa-
tients with iPAH. They also concluded that measurement
of this compound in urinary samples of asymptomatic
children with family history of iPAH can help in early de-
tection of disease process [4].
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Oxidized lipids Oxidized lipids such as hydroxyeicosa-
tetraenoic (HETE) and hydroxyoctadecadienoic acids
(HODE) have an established role in the pathogenesis of
vascular diseases. Recently, the research in our lab showed
that miR193 overexpression can lead to a significant im-
provement in the severity of pulmonary hypertension [42].
We studied two rodent models of PH and discovered that
plasma concentrations of oxidized lipids such as HETEs
and HODEs were significantly elevated in PH. MicroRNA
analysis revealed that miR193 was significantly downregu-
lated in the lung tissue and serum from both patients with
PAH and rodents with PH. Apolipoprotein A-I mimetic
peptide 4 F treatment reduced the concentrations of oxi-
dized lipids and rescued preexisting PH in both rodent
models through miR193 overexpression in the lungs. We
concluded that A-I mimetic peptide 4 F and microRNA-
193-3p may have therapeutic implications in patients with
PAH. Furthermore, oxidized lipids may serve as plasma
biomarkers for PAH. Recently, we and our collaborators
at UCLA found significantly increased plasma concentra-
tions of the eicosanoids 9-HODE, 13-HODE, 5-HETE,
12-HETE, and 15-HETE in patients with PAH [38]. The
study has further implicated the putative role of oxidative
stress and inflammation in the pathobiology of PAH.
Other oxidative stress related markers Reis et al., looked
at oxidative-stress biomarkers in patients suffering from
PAH and found that inflammation and oxidative stress
were present in patients with PAH, as confirmed by
increased lipid peroxidation, reduced GSH, and low
concentrations of vitamin E [36].
Metabolic biomarkers
Circulating amino acid profile and fischer ratio Plasma
amino acid concentrations are being studied in an effort
to look for a biomarker in patients with PAH. In a
study by Yanagisawa et al., distinct patterns of amino
acids (aminogram) of 140 patients with PAH were stud-
ied [52]. The authors also measured the Fischer ratio
(branched-chain amino acids/aromatic amino acids).
The study concluded that patients with PAH have a
recognizably different aminogram and Fischer ratio was
decreased with increasing severity of disease. However
this study has a few limitations and in order to confirm
aminogram as a potential biomarker for PAH a large-scale
investigation is needed. Some of the major limitations of
this study include the patients with PH receiving PH-
specific drugs and diuretics; that may have augmented the
differences in amino acid profile and Fischer ratios. In
addition, NYHA functional class and gender were not
evenly distributed among the patients with PH and the
majority of this study population comprised patients with
CTEPH, and thus, the results of this study in all enrolled
patients might have been affected or masked by multiple
etiologic conditions. Furthermore, the absolute change in
amino acid levels between PH and healthy control sub-
jects was generally small although statistically significant.
Metabolomics related markers Metabolomics involves
study of the metabolic activities and their end products
or metabolites at the cellular concentration. As all the
disease processes start with the malfunction at the cellular
concentration including the oxidative response, metabolo-
mics can provide a breakthrough for diagnosis and prog-
nosis of the medical problems. A few studies have been
performed to study the metabolic profiling and its relation
with the cardiovascular diseases including PAH. The
metabolites of interest included all from simple lipids,
glucose to small molecules like cGMP. There is still a
need to perform large-scale studies to detect a particular
role of metabolic profiling in diagnosis and prognosis of
diseases. The study by Lewis et al. showed that metabolo-
mics along with high-throughput genome sequencing and
RNA expression analysis can also be helpful to discover
more biomarkers of great interest for PAH and RV dys-
function [20]. Recently, Lewis et al. sought to determine
whether metabolite profiling could identify plasma
signatures of right ventricular-pulmonary vascular (RV-PV)
dysfunction. They measured plasma concentrations of 105
metabolites using targeted mass spectrometry in 71 individ-
uals. Metabolic profiling identified reproducible signatures
of RV-PV dysfunction, highlighting both new biomarkers
and pathways for further functional characterization [21].
Tryptophan metabolites In a recent study, Lewis et
al. Showed that right ventricular-pulmonary vascular
hemodynamic parameters correlate strongly with a
subset of tryptophan metabolites. A strong correlation was
found with the concentrations of the 4 tryptophan
metabolites of the indoleamine 2,3-dioxygenase pathway:
kynurenine, kynurenate, anthranilate, and quinolinate [21].
Ghrelin Yang et al. found that plasma ghrelin concentra-
tions were elevated in IPAH patients. Ghrelin is a peptide
hormone produced in the gastrointestinal tract and regu-
lates appetite. Increased ghrelin concentrations correlated
positively with right ventricle diameter, pulmonary arterial
systolic pressure, plasma N-terminal brain natriuretic pep-
tide, endothelin-1 and nitric oxide concentrations [53].
Extracellular matrix related biomarkers
Schumann et al. in 2010 tested the hypothesis that plasma
concentration of matrix metalloproteinase (MMP)-2, tis-
sue inhibitor of matrix metalloproteinases (TIMP)-4 and
tenascin C (TNC) might be useful as biomarkers for asses-
sing the severity of PH. Therefore, the concentrations of
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MMP-2, TIMP-4, TNC and NTproBNP of 36 PH patients
were compared with those of 44 age- and gender-matched
healthy volunteers. Interestingly, in PH patients, signifi-
cantly elevated plasma concentrations of MMP-2, TIMP-
4, TNC and NTproBNP were detected. In particular,
TIMP-4 was significantly increased in patients with higher
NYHA classification, and in patients with severe right
ventricular hypertrophy [41]. Hessel et al., in 2009 found
that Monocrotaline-induced PH and RV failure was asso-
ciated with an upregulation of myocardial Tenascin C
gene expression, resulting in re-expression of myocardial
Tenascin C protein concentrations, and elevated Tenascin
C plasma concentrations. As RV ejection fraction corre-
lated significantly with Tenascin C plasma concentrations,
they suggested plasma concentrations of Tenascin C may
serve as a marker of PH-induced RV failure [11].
Volatile compounds in exhaled breath condensate in PAH
Mansoor et al., compared exhaled breath condensate
(EBC) samples from 30 age-matched normal healthy
individuals and 27 NYHA class III and IV IPAH pa-
tients and analyzed volatile organic compounds in EBC
samples using gas chromatography/mass spectrometry.
There were 62 unique compounds in the control group,
32 unique compounds in the IPAH group, and 14 in-
common compounds between groups. Six compounds
significantly correlated with pulmonary hemodynamic
variables such as mPAP, PVR or PAWP important in
IPAH diagnosis [26].
Conclusions
The search for a non-invasive biomarker for pulmonary
hypertension is ongoing. Although a number of promising
pre-clinical and clinical biomarkers for PAH have been
mentioned in this review, the challenges of validation and
correlation with hemodynamic parameters remain (Fig. 1).
Large clinical studies are needed to validate the promising
biomarkers. In addition, more sensitive and specific assays
will help in validation of the biomarkers. It is likely that a
single biomarker may not provide all the relevant
Fig. 1 Schematic diagram showing different groups of biomarkers for pulmonary hypertension including markers related to inflammation, heart function,
epigenetics, oxidative stress, endothelial function, metabolism, volatile compounds, and extracellular matrix
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information required for an individual patient, and the po-
tential for a biomarker panel is of considerable interest.
There is a possibility of discovering biomarkers for PAH
corresponding to various compartments within the lung
such as the pulmonary vasculature, inflammatory infil-
trate, and extracellular matrix or biomarkers related to RV
function. Biomarker/s that can be detected by a simple
blood test or breath condensate and correlate/s with dis-
ease severity, progression and response to therapy may re-
sult in significant cost reduction and improved patient
outcomes.
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